RxDoctor Payments Data

April Bowers, NP

Nurse Practitioner · Holyoke, MANPI 1710178348

Payments from drug & device makers

$1,363in general payments, 2019–2025

Across 36 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$481
  • Bristol Myers Squibb$157
  • AbbVie$131
  • Janssen Scientific Affairs, LLC$125
  • E.r. Squibb & Sons, L.L.C.$104
  • Eisai Inc.$98
  • plus $267 from 7 others

What the payments were for

  • Food & beverage$1,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,363 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$19,953
Medicare patients
167
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide651$392,738
CreonLipase/Protease/Amylase265$299,275
Humira PenAdalimumab14$85,713
ViberziEluxadoline54$84,509
TrulancePlecanatide101$59,360
Dexlansoprazole DrDexlansoprazole125$27,523
Alosetron Hcl30$24,321
MotegrityPrucalopride Succinate21$16,533
ZenpepLipase/Protease/Amylase13$15,441
Dicyclomine Hcl405$11,934
DexilantDexlansoprazole26$11,445
TrulicityDulaglutide12$11,432
Omeprazole597$10,809
Sucralfate204$10,755
Pantoprazole Sodium657$10,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$131$776,522970 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$59$59,360101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Holyoke

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →